.png){kind=icon}
.png){kind=icon}
Return
Treatment persistence after switching between anti-tumor necrosis factor agents and tofacitinib in ulcerative colitis: A nationwide claims-based cohort study in South Korea
.png){kind=icon}
PRE
AI
J
A
H
B
K
DOI：10.1177/17562848261478114.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
<jats:sec>
<jats:title>Background</jats:title>
<jats:p>The optimal sequencing of advanced therapy in ulcerative colitis (UC) remains unclear. Data comparing different sequencing including the use of tofacitinib as first-line therapy remain scarce.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Objectives</jats:title>
<jats:p>We compared the treatment persistence of two therapeutic strategies: anti-tumor necrosis factor (anti-TNF) agents to tofacitinib (A→T) versus tofacitinib to anti–TNF agents (T→A).</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Design</jats:title>
<jats:p>We conducted a retrospective, nationwide, claims-based cohort study using data from the Korean Health Insurance Review and Assessment database.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods</jats:title>
<jats:p>We included adult UC patients initiating anti-TNF agents or tofacitinib as first-line therapy. The primary outcome was second-line treatment persistence, using Kaplan-Meier method and multivariable Cox models to estimate adjusted hazard ratios (aHRs). Propensity score matching balanced baseline characteristics.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results</jats:title>
<jats:p>A total of 314 patients were included (A→T, n=273; T→A, n=41). The T→A group was younger (33.0 vs 42.0 years; P=0.02), had lower concomitant use of corticosteroids at first-line therapy (36.59% vs 65.57%; P<0.01), and had shorter duration of total advanced therapy (3.50 vs 4.29 years; P<0.01). After propensity score matching, the persistence of second-line therapy was significantly longer in the A→T group compared with the T→A group (aHR, 2.48; 95% CI, 1.18–5.21; P=0.02), whereas the persistence of first-line therapy did not differ significantly between the two sequences (aHR, 1.18; 95% CI, 0.76–1.85; P=0.46). Progression to third-line therapy occurred more frequently in the T→A group than in the A→T group (41.5% vs 19.8%).</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusion</jats:title>
<jats:p>In Korean UC patients, switching from anti-TNF agents to tofacitinib was associated with longer second-line treatment persistence than the reverse sequence.</jats:p>
</jats:sec>
Journal
T
IF:
3.4
Papers:
1.5K
Citations:
3.9K
Organization
Cited Papers